Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

摘要: The association between CYP2D6 genotype and outcome in breast cancer patients treated with adjuvant tamoxifen remains controversial. We assessed the influence of comprehensive versus limited context adherence co-medication a large cohort 618 patients. Genotyping 33 alleles used two archival cohorts from tamoxifen-treated women invasive (Dundee, n = 391; Manchester, 227). Estimates for recurrence-free survival (RFS) were calculated based on inferred phenotypes using Kaplan–Meier Cox proportional hazard models, adjusted nodal status tumour size. Patients at least one reduced function allele (60%) or no functional (6%) had non-significant trend worse RFS: ratio (HR) 1.52 (CI 0.98–2.36, P 0.06). For post-menopausal monotherapy, HR recurrence was 1.96 1.05–3.66, 0.036). However, RFS analysis to four common allelic variants longer significant (P 0.39). effect increased by adjusting therapy, but not significantly changed when co-administration potent inhibitors CYP2D6. Comprehensive genotyping therapy may be useful identify most likely benefit tamoxifen.